									Sheet _i	01 4	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY, DOCKET NO.		LICATION NO.			
						690121.408USPC 10/587,776					
INCOMMENTAL DISCUSSION OF THE PARTY						APPLICANTS Masste Miyeke et al.					
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)						Masato Miyake et al. FILING DATE GROUP ART UNIT					
اريو APR 0 9 2008			••			June 18, 2007 1642					
U.S. PAT											
Control											
*EXAMINER INITIAL			CUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
· · · · · · · · · · · · · · · · · · ·	1										
AA FOREICN DATENTS DOCUMENTS											
FOREIGN PATENT DOCUMENTS											
		DO	CUMENT NUMBER DATE		COUNTRY				TRANSLATION YES NO		
	АВ	WO	97/11604 A1	04/03/97	WIPO						
	AC WO 00/01836 A1			01/13/00	WIPO						
	AD	WO	01/04268 A1	01/18/01	WIPO						
	AE	WO	01/020015 A1	03/22/01	WIPO						
	AF	wo	02/018609 A3	03/07/02	WIPO						
	AG	WO	02/083854 A2	10/24/02	WIPO						
	AH	WO	03/000297 A1	01/03/03	WIPO					 	
	AI	wo	2004/061111 A1	07/22/04	WIPO			-			
			OTHE	R PRIOR A	RT (Including	, Author, Title, Date, Pertinent Pa	iges, Etc.)				
					"Potential tumor-targeting peptide vector of histidylated oligolysine						
	conjugated to a tumor-homing RGD motif," Cancer Gene Therapy 8: 783-787, 200										
	. AK		Baghdoyan, S. et al., "Quantitative analysis of highly parallel transfection in cell								
	-	_	i	microarrays," Nucleic Acids Research 32(9): 1-8, 2004.							
	AL		Fortunati, E. et al., "A multi-domain protein for β ₁ integrin-targeted DNA delivery," Gene								
			Therapy 7: 1505-1515, 2000.								
	Harbottle, R. et al., "An RGD-Oligolysine Peptide: A Prototype Construct for I								ntegrin	i -	
	'		Mediated Gene Delivery," Human Gene Therapy 9: 1037-1047, May 1, 1998.								
	Kunath K et al. "Integrin targeting using RGD-PEI conjugates for in vitro gene trans									fer."	
	J. Gene Med. 5: 588-599, 2003.								,		
	AO Miyake, M. et al., "Transfection Array technology and the application for post-genetic										
research," Tissue Engineering Research Center, pp							69-174, 2003 [Abstract].				
EXAMIN	EXAMINER DATE CONSIDERED										
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).											
		COMIC	minance and not consid	icica, include coj	iy oi uus iom v	with next communication to applic	cani(s).				

U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. APPLICATION NO. PATENT AND TRADEMARK OFFICE 690121.408USPC 10/587,776 APPLICANTS Masato Miyake et al. INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE **GROUP ART UNIT** June 18, 2007 1642 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DOCUMENT NUMBER DATE SUBCLASS NAME **CLASS** INITIAL IF APPROPRIATE BA FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER DATE COUNTRY YES NO BB BC BD BE BF BG вн ы OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Moritz, T. et al., "Bone Marrow Extracellular Matrix Molecules Improve Gene Transfer into ΒJ Human Hematopoietic Cells via Retroviral Vectors," Journal of Clinical Investigation *93*(4):1451-1457, 1994. Moritz, T. et al., "Fibronectin Improves Transduction of Reconstituting Hematopoietic Stem BK Cells by Retroviral Vectors: Evidence of Direct Viral Binding to Chymotryptic Carboxy-Terminal Fragments," Blood 88(3):855-862, August 1, 1996. Mousses, S. et al., "RNAi Microarray Analysis in Cultured Mammalian Cells," Genome BLResearch 13: 2341-2347, 2003. Schneider, H. et al., "Targeted gene delivery into α₉β₁-integrin-displaying cells by a ВМ synthetic peptide," FEBS Letters 458: 329-332, 1999. Yamauchi, F. et al., "Fabrication of Microarrays for Transfection of Nucleic Acids into BN Cells," Polymer Preprints 52(13): 3858-3859, 2003. **EXAMINER DATE CONSIDERED** * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).